MetaCap

AgomAb Therapeutics NV ADR (AGMB)

NASDAQ: AGMBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

5.45-0.17 (-3.02%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AGMB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$268.40M
EPS (TTM)
-$2.08
52-week range
5.39 – 17.82
Day range
5.39 – 5.78
Volume / Avg
188.94K / 208.99K
Beta
—

52-week range

$5.39$17.82

AGMB stock today

Shares of AgomAb Therapeutics NV (AGMB) finished lower on Nov 20 at $5.45, a drop of 3.02% or $0.17 per share, versus the S&P 500's 3.70% decline. Shares are 69.4% below their 52-week high of $17.82, set on Jun 29, 2026 and 1.1% above the 52-week low of $5.39, near the bottom of the past year's range. AgomAb Therapeutics NV has posted a net loss over the last twelve months (EPS of -$2.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About AgomAb Therapeutics NV

Company profile

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Tim Knotnerus MSc, Ph.D.
Headquarters
Antwerp
Employees
62
IPO year
2026
Website
agomab.com

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$37.67+591.19%

  • Strong buy 3
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $28.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

AGMB news

All AGMB news

AgomAb Therapeutics NV peers

Health Care sector
AGMB peer companies
CompanyPrice% ChgMarket capCompare
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs AGMB
AGENAgenus Inc.5.97-2.77%$270.12Mvs AGMB
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs AGMB
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs AGMB
DTILPrecision BioSciences Inc.7.40+7.09%$282.46Mvs AGMB
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs AGMB
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs AGMB
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs AGMB

Indexes, lists and sector

AgomAb Therapeutics NV stock FAQ

What is AgomAb Therapeutics NV's stock price today?

AGMB last traded at $5.45 as of Nov 20, 4:00 PM EST, down 3.02% on the day. Prices are delayed at least 15 minutes.

Who is AgomAb Therapeutics NV's CEO?

Dr. Tim Knotnerus MSc, Ph.D. is the chief executive officer of AgomAb Therapeutics NV ADR, which has about 62 employees.

What is the AGMB 52-week high?

The 52-week high for AGMB is $17.82 and the 52-week low is $5.39. The stock is currently 69.4% below its high.

Compare AGMB